NEVRO CORP (NVRO)
US64157F1030 - Common Stock
Taking everything into account, NVRO scores 2 out of 10 in our fundamental rating. NVRO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NVRO has a bad profitability rating. Also its financial health evaluation is rather negative. NVRO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year NVRO has reported negative net income.
NVRO had a negative operating cash flow in the past year.
NVRO had negative earnings in 4 of the past 5 years.
In multiple years NVRO reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of NVRO (-11.64%) is comparable to the rest of the industry.
NVRO has a Return On Equity (-25.33%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.64% | ||
| ROE | -25.33% | ||
| ROIC | N/A |
ROA(3y)-12.29%
ROA(5y)-13.9%
ROE(3y)-24.6%
ROE(5y)-28.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 68.02%, NVRO is doing good in the industry, outperforming 75.40% of the companies in the same industry.
In the last couple of years the Gross Margin of NVRO has remained more or less at the same level.
NVRO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
NVRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVRO has more shares outstanding
Compared to 5 years ago, NVRO has more shares outstanding
NVRO has a worse debt/assets ratio than last year.
2.2 Solvency
NVRO has an Altman-Z score of -0.52. This is a bad value and indicates that NVRO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.52, NVRO is in line with its industry, outperforming 41.18% of the companies in the same industry.
A Debt/Equity ratio of 0.81 indicates that NVRO is somewhat dependend on debt financing.
NVRO has a worse Debt to Equity ratio (0.81) than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.52 |
ROIC/WACCN/A
WACC6.65%
2.3 Liquidity
A Current Ratio of 5.02 indicates that NVRO has no problem at all paying its short term obligations.
The Current ratio of NVRO (5.02) is better than 75.40% of its industry peers.
NVRO has a Quick Ratio of 3.76. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
NVRO has a better Quick ratio (3.76) than 73.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.02 | ||
| Quick Ratio | 3.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 38.11% over the past year.
Looking at the last year, NVRO shows a decrease in Revenue. The Revenue has decreased by -0.86% in the last year.
The Revenue has been growing slightly by 1.88% on average over the past years.
EPS 1Y (TTM)38.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.92%
Revenue 1Y (TTM)-0.86%
Revenue growth 3Y5.51%
Revenue growth 5Y1.88%
Sales Q2Q%-6.69%
3.2 Future
NVRO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.51% yearly.
NVRO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.81% yearly.
EPS Next Y3.58%
EPS Next 2Y0.9%
EPS Next 3Y5.04%
EPS Next 5Y7.51%
Revenue Next Year-4.34%
Revenue Next 2Y-1.88%
Revenue Next 3Y0.14%
Revenue Next 5Y2.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NVRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVRO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.9%
EPS Next 3Y5.04%
5. Dividend
5.1 Amount
No dividends for NVRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEVRO CORP
NYSE:NVRO (12/23/2024, 12:32:47 PM)
3.715
-0.08 (-1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.58%
Inst Owner Change3.47%
Ins Owners2.07%
Ins Owner Change-0.4%
Market Cap139.20M
Analysts50.48
Price Target9.39 (152.76%)
Short Float %7.78%
Short Ratio5.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.29%
Min EPS beat(2)24.11%
Max EPS beat(2)50.46%
EPS beat(4)4
Avg EPS beat(4)42.62%
Min EPS beat(4)24.11%
Max EPS beat(4)50.46%
EPS beat(8)7
Avg EPS beat(8)23.61%
EPS beat(12)11
Avg EPS beat(12)213.06%
EPS beat(16)15
Avg EPS beat(16)163.35%
Revenue beat(2)1
Avg Revenue beat(2)-1.39%
Min Revenue beat(2)-4.87%
Max Revenue beat(2)2.09%
Revenue beat(4)3
Avg Revenue beat(4)0.13%
Min Revenue beat(4)-4.87%
Max Revenue beat(4)2.09%
Revenue beat(8)4
Avg Revenue beat(8)0.44%
Revenue beat(12)5
Avg Revenue beat(12)0.08%
Revenue beat(16)7
Avg Revenue beat(16)0%
PT rev (1m)-5.96%
PT rev (3m)-13.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-164.42%
EPS NY rev (1m)10.74%
EPS NY rev (3m)10.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.66%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.51 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.52
Fwd EYN/A
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS11.19
BVpS7.3
TBVpS5.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.64% | ||
| ROE | -25.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | N/A |
ROA(3y)-12.29%
ROA(5y)-13.9%
ROE(3y)-24.6%
ROE(5y)-28.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 93.81% | ||
| Cap/Sales | 2.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.02 | ||
| Quick Ratio | 3.76 | ||
| Altman-Z | -0.52 |
F-Score4
WACC6.65%
ROIC/WACCN/A
Cap/Depr(3y)165.59%
Cap/Depr(5y)139.75%
Cap/Sales(3y)2.36%
Cap/Sales(5y)1.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.92%
EPS Next Y3.58%
EPS Next 2Y0.9%
EPS Next 3Y5.04%
EPS Next 5Y7.51%
Revenue 1Y (TTM)-0.86%
Revenue growth 3Y5.51%
Revenue growth 5Y1.88%
Sales Q2Q%-6.69%
Revenue Next Year-4.34%
Revenue Next 2Y-1.88%
Revenue Next 3Y0.14%
Revenue Next 5Y2.81%
EBIT growth 1Y18.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.08%
EBIT Next 3Y27.09%
EBIT Next 5Y18.2%
FCF growth 1Y-452.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-304.68%
OCF growth 3YN/A
OCF growth 5YN/A